Tenofovir disoproxil fumarate for the treatment of hepatitis B infection

Drugs of Today

Volumn 45, Issue 9, 2009, Pages 679-685

  Adusumilli, Sarojini ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADEFOVIR; ATAZANAVIR; CIDOFOVIR; DIDANOSINE; EMTRICITABINE; ENTECAVIR; GANCICLOVIR; LAMIVUDINE; PROBENECID; TELBIVUDINE; TENOFOVIR DISOPROXIL; TRIMETHOPRIM; VALACICLOVIR; VALGANCICLOVIR;

ABDOMINAL PAIN; ACUTE KIDNEY TUBULE NECROSIS; AREA UNDER THE CURVE; BACKACHE; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UPTAKE; EUROPEAN UNION; FATIGUE; GASTROINTESTINAL SYMPTOM; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERSTITIAL NEPHRITIS; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEPHROGENIC DIABETES INSIPIDUS; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTOPENIA; TUBULAR DYSFUNCTION; UNITED STATES;

ADENINE; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HEPATITIS B, CHRONIC; HUMANS; PHOSPHONIC ACIDS; PRODRUGS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 75749155056     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.9.1416420     Document Type: Review

References (40)

1. Lok, A.S., McMahon, B.J. Chronic hepatitis B: Update 2009. Hepatology 2009, 50(3): 661-2.
2. Dienstag, J.L. Hepatitis B virus infection. N Engl J Med 2008, 359(14): 1486-500.
3. Delaney, W.E., Borroto-Esoda, T. Therapy of chronic hepatitis B: Trends and developments. Curr Opin Pharmacol 2008, 8(5): 532-40.
4. Lok, A.S., McMahon, B.J. Chronic hepatitis B. Hepatology 2007, 45(2): 507-39.
5. Reynaud, L., Carleo, M.A., Talamo, M., Borgia, G. Tenofovir and its potential in the treatment of hepatitis B virus. Ther Clin Risk Manag 2009, 5(1): 177-85.
6. Jenh, A.M., C.L. Thio, C.L., Pham, P.A. Tenofovir for the treatment of hepatitis B virus. Pharmacotherapy 2009, 29(10): 1212-27.
7. Degertekin, B., Lok, A.S. Indications for therapy in hepatitis B. Hepatology 2009, 49(5 Suppl): S129-37.
8. Chapman, T., McGavin, J., Noble, S. Tenofovir disoproxil fumarate. Drugs 2003, 63(15): 1597-608.
9. Grim, S.A., Romanelli, F. Tenofovir disoproxil fumarate. Ann Pharmacother 2003, 37(6): 849-59.
10. Kearney, B.P., Flaherty, J.F., Shah, J. Tenofovir disoproxil fumarate: Clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004, 43(9): 595-612.
11. De Clercq, E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003, 16(4): 569-96.
12. Robbins, B.L., Wilcox, C.K., Fridland, A., Rodman, J.H. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 2003, 23(6): 695-701.
13. Stephan, C. Experience with tenofovir disoproxil fumarate for antiretroviral therapy. Expert Opin Pharmacother 2008. 9(7): 1197-209.
14. Kearney, B.P., Sayre, J.R., Flaherty, J.F., Chen, S.S., Kaul, S., Cheng, A.K. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J Clin Pharmacol 2005, 45(12): 1360-7.
15. Delaney, W.E., Ray, A.S., Yang, H., Qi, X., Xiong, S., Zhu, Y., Miller, M.D. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006, 50(7): 2471-7.
16. Pham, P.A., Gallant, J.E. Tenofovir disoproxil fumarate for the treatment of HIV infection. Expert Opin Drug Metab Toxicol 2006, 2(3): 459-69.
17. Núñez, M, Pérez-Olmeda, M., Díaz, B., Ríos, P., González-Lahoz, J., Soriano, V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002, 16(17): 2352-4.
18. Ristig, M.B., Crippin, J., Aberg, J.A. et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002, 186(12): 1844-1847.
19. Benhamou, Y., Tubiana, R., Thibault, V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003, 348(2): 177-8.
20. Nelson, M., Portsmouth, S., Stebbing, J. et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003, 17(1): F7-F10.
21. Dore, G.J., Cooper, D.A., Pozniak, A.L. et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004, 189(7): 1185-92.
22. van Bommel, F., Wünsche, T., Mauss, S. et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004, 40(6): 1421-5.
23. Lacombe, K., Gozlan, J., Boelle, P.Y., Serfaty, L., Zoulim, F., Valleron, A.J., Girard, P.M. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS 2005, 19(9): 907-15.
24. Stephan, C., Berger, A., Carlebach, A. et al. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother 2005, 56(6): 1087-93.
25. Benhamou, Y., Fleury, H., Trimoulet, P. et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006, 43(3): 548-55.
26. Peters, M.G., Andersen, J., Lynch, P. et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006, 44(5): p. 1110-1116.
27. Jain, M.K., Parekh, N.K., Hester, J., Lee, W.M. Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. AIDS Patient Care STDS 2006, 20(12): 817-22.
28. Lacombe, K., Gozlan, J., Boyd, A. et al. Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients. Antivir Ther 2008, 13(5): 705-13.
29. Matthews, G.V., Avihingsanon, A., Lewin, S.R. et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008, 48(4): 1062-9.
30. Kuo, A., Dienstag, J.L., Chung, R.T. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004, 2(3): 266-72.
31. van Bommel, F., Zöllner, B., Sarrazin, C. et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006, 44(2): 318-25.
32. Santos, S.A., Uriel, A.J., Park, J.S., Lucas, J., Carriero, D., Jaffe, D., Dieterich, D.T. Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an odefovir-containing regimen. Eur J Gastroenterol Hepatol 2006, 18(12): 1247-53.
33. Schildgen, O., Sirma, H., Funk, A. et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006, 354(17): 1807-12.
34. Choe, W.H., Kwon, S.Y., Kim, B.K. et al. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. Liver Int 2008, 28(6): 814-20.
35. Marcellin, P., Heathcote, E.J., Buti, M. et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359(23): 2442-55.
36. Kuo, A., Dienstag, J.L., Chung, R.T. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004, 2(3): 266-72.
37. Marcellin, P., Heathcote, E.J., Buti, M. et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359(23): 2442-2445.
38. Gerolami, R., Bourliere, M., Cotson, P. et al. Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: Report of two cases. Antivir Ther 2006, 11(8): 1103-6.
39. Qi, X., Xiong, S., Yang, H., Miller, M., Delaney, W.E 4th. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007, 12(3): 355-62.
40. Brunelle, M.N., Jacquard, A.C., Pichoud, C. et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005, 41(6): 1391-1398.